Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Intellia Therapeutics (NASDAQ:NTLA) Share Price
News headlines about Intellia Therapeutics (NASDAQ:NTLA) have been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intellia Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.8341214344857 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern’s rankings:
- Sector Percentage Losers- Incyte Corporation (NASDAQ:INCY), Intellia Therapeutics, Inc. (NASDAQ:NTLA), Aceto … (journalfinance.net)
- Intellia Therapeutics Earns RS Rating Upgrade (investors.com)
- CRISPR players say appeals court decision did not determine inventors (seekingalpha.com)
- Analysts Anticipate Intellia Therapeutics Inc (NTLA) Will Post Quarterly Sales of $12.73 Million (americanbankingnews.com)
Shares of NASDAQ NTLA traded up $0.08 during midday trading on Friday, reaching $31.05. The stock had a trading volume of 425,448 shares, compared to its average volume of 442,033. The stock has a market cap of $1.31 billion, a PE ratio of -16.52 and a beta of 3.09. Intellia Therapeutics has a 12-month low of $16.33 and a 12-month high of $35.99.
A number of analysts have commented on NTLA shares. ValuEngine raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. BidaskClub raised shares of Intellia Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 16th. Zacks Investment Research raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a report on Saturday, August 4th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $57.50 target price on shares of Intellia Therapeutics in a report on Friday, August 24th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Intellia Therapeutics has an average rating of “Buy” and a consensus target price of $39.50.
In other news, Director Jean Francois Formela sold 6,686 shares of the stock in a transaction on Monday, July 16th. The shares were sold at an average price of $31.17, for a total value of $208,402.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 12.80% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
See Also: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.